Drug Profile
Research programme: lung cancer therapeutics - ProMIS Neurosciences/MD Anderson Cancer Center
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Amorfix Life Sciences; University of Texas M. D. Anderson Cancer Center
- Developer ProMIS Neurosciences; University of Texas M. D. Anderson Cancer Center
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lung cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Lung-cancer in USA (Parenteral)
- 14 Jul 2015 Amorfix Life Sciences is now called ProMIS Neurosciences
- 25 Apr 2013 Early research in Lung cancer in USA (Parenteral)